Abstract | AIM: To evaluate the clinical utility of serum fibrosis markers, including YKL-40, in patients with HCV-associated liver disease. METHODS: RESULTS: The increase in serum levels of all markers, particularly HA, was correlated with the progression of liver fibrosis (for type IV collagen, F = 9.076, P<0.0001; for PIIIP, F = 9.636, P<0.0001; for HA, F = 13.128, P<0.0001; and for YKL-40, F = 8.016, P<0.0001). YKL-40 had strong correlation with HA (r = 0.536, P<0.0001). Based on the receiver operating curve (ROC), the ability of serum HA exceeded the abilities of other serum markers to determine fibrosis score 4 from fibrosis score 0-3 (AUC = 0.854). While YKL-40 was superior to other fibrosis markers for predicting severe fibrosis (F2-F4) from mild fibrosis (F0-F1) (YKL-40, AUC = 0.809; HA, AUC = 0.805). After IFN therapy, only YKL-40 values significantly decreased not only in the responder group, but also in the nonresponder group (P = 0.03). CONCLUSION:
|
Authors | Yukiko Saitou, Katsuya Shiraki, Yutaka Yamanaka, Yumi Yamaguchi, Tomoyuki Kawakita, Norihiko Yamamoto, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 11
Issue 4
Pg. 476-81
(Jan 28 2005)
ISSN: 1007-9327 [Print] United States |
PMID | 15641129
(Publication Type: Journal Article)
|
Chemical References |
- Adipokines
- Antiviral Agents
- Biomarkers
- CHI3L1 protein, human
- Chitinase-3-Like Protein 1
- Glycoproteins
- Lectins
- Interferons
|
Topics |
- Adipokines
- Adult
- Aged
- Antiviral Agents
(therapeutic use)
- Biomarkers
- Biopsy
- Chitinase-3-Like Protein 1
- Female
- Glycoproteins
(blood)
- Hepatitis C, Chronic
(blood, drug therapy, pathology)
- Humans
- Interferons
(therapeutic use)
- Lectins
- Liver Cirrhosis
(blood, drug therapy, pathology)
- Male
- Middle Aged
- Predictive Value of Tests
- Sensitivity and Specificity
- Severity of Illness Index
|